08th March 2022 | Pharma Updates
Medtronic Introduces the MiniMed 780G System with SmartGuard Technology in India to Simplify Type 1 Diabetes Management
Automatic insulin delivery, automatic correction boluses, and Bluetooth connectivity are among the features of India’s first Advanced Hybrid Closed Loop Insulin Pump System.
Zydus' Oxemia for CKD-induced anaemia has been approved by the DCGI
The Drug Controller General of India (DCGI) has accepted Zydus Lifesciences’ new drug application (NDA) for Oxemia (Desidustat), a first-of-its-kind oral treatment for anaemia caused by chronic kidney disease.
Natco Pharma has announced the release of the first generic version of the top-selling cancer medication Revlimid
Natco Pharma, in collaboration with its marketing partner Arrow International, announced the launch of the first generic version of Celgene’s (now Bristol Myers Squibb) top-selling cancer medicine Revlimid.
Lipid nanoparticles are stretching the bounds of modern medicine
One advantage of this technology is that lipid-based nanoparticles can be created particularly to overcome the constraints provided by the human body’s innate biological barriers, either systemic or cellular.
Experts recommend baricitinib for COVID treatment
Baricitinib, an anti-inflammatory medication, is typically used to treat rheumatoid arthritis. According to the BBC, trials show that it can reduce the risk of death by around a fifth among individuals requiring hospital care for severe Covid.
Scientists discover new gene differences in severe COVID patients
In a large study published recently, scientists identified 16 novel genetic variants in persons who acquired severe COVID-19, which could help researchers create treatments for severely sick patients.
WHO recommends the RTS, S/AS01 malaria vaccine for children living in moderate to high transmission areas
WHO published an updated position paper on the RTS,S/AS01 (RTS,S) malaria vaccine in order to expand its use among children living in areas with moderate-tohigh P. falciparum malaria transmission.
FDA has approved Axonics's recharge-free sacral neuromodulation system
Axonics, a global medical technology company announced that the FDA has authorised its newly created, long-lasting, recharge-free sacral neuromodulation implantable neurostimulator.
FDA's approval of Cilta-Cel accelerates the development of a cure for multiple myeloma
Sundar Jagannath, MBBS, discusses the relevance of the FDA’s approval of ciltacabtagene autoleucel, critical adverse effects to be cautious of, and where the medication fits within current and future therapeutic paradigms.
Neoadjuvant Nivolumab and Platinum Doublet Chemotherapy Are Approved by the FDA for Early-Stage NSCLC
In the neoadjuvant context, the FDA approved nivolumab in conjunction with platinum-doublet chemotherapy for adult patients with resectable NSCLC. This is the first time the FDA has approved neoadjuvant therapy for early-stage NSCLC.